Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro

Xenobiotica

Volumn 44, Issue 9, 2014, Pages 792-803

  Youssef, Amir S ^a   Parkman, Henry P ^a   Nagar, Swati ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A4; Domperidone; Drug drug interaction; Ondansetron; Pioglitazone

Indexed keywords

CYTOCHROME P450 3A4; DOMPERIDONE; ONDANSETRON; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; CYTOCHROME P450 3A; GASTROINTESTINAL AGENT;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; EVALUATION STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; SUICIDE SUBSTRATE; ADVERSE DRUG REACTION; DRUG EFFECTS; DRUG INTERACTION; HYDROXYLATION; LIQUID CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY;

ANTIEMETICS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DOMPERIDONE; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL AGENTS; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; MICROSOMES, LIVER; ONDANSETRON; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 84905394323     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.899406     Document Type: Article

References (57)

1. Barone JA. (1999). Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 33:429-40.
2. Boyce MJ, Baisley KJ, Warrington SJ. (2011). Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 73:411-21.
3. Bozigian H, Pritchard J, Gooding A, Pakes G. (1994). Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci 83:1011-13.
4. Brown H, Galetin A, Hallifax D, Houston J. (2006). Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-50.
5. Brown H, Ito K, Galetin A, Houston J. (2005). Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-18.
6. Budde K, Neumayer H, Fritsche L, et al. (2003). The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-74.
7. Chang SY, Fancher RM, Zhang H, Gan J. (2010). Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica 40:138-45.
8. Choi J, Burm J. (2008). Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Arch Pharm Res 31:1200-4.
9. Chu V, Einolf HJ, Evers R, et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339-54.
10. Cornish-Bowden A. (1974). A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143-4.
11. Dixon C, Colthup P, Serabjit-Singh C, et al. (1995). Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225-30.
12. Drolet B, Rousseau G, Daleau P, et al. (2000). Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102:1883-5.
13. Fischer V, Vickers A, Heitz F, et al. (1994). The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269-74.
14. Food and Drug Administration. ( 2012). Draft guidance for industry. Drug interaction studies-study design, data analysis, and implications for dosing and labelling recommendations. Available from: http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegula toryInformation/Guidances/UCM292362.pdf [last accessed 24 August 2012].
15. Friedenberg F, Parkman H. (2006). Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol 9: 295-304.
16. Gibaldi M, Perrier D. (1982). Pharmacokinetics. Dekker.
17. Glazer N. (2000). Pioglitazone does not induce cytochrome P450 isoform CYP3A4 [Rapid Responses]. Available from: http://www.bmj.com/rapid-response/ 2011/10/28/pioglitazone-does-not-induce-cytochrome-p450-isoform-cyp3a4 [last accessed 10 March 2014].
18. Goodman LS, Hardman JG, Limbird LE, Gilman AG. (2001). Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill.
19. Hanefeld M. (2001). Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 121:19-25.
20. Horowitz M, Harding PE, Maddox AF, et al. (1989). Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:151-9.
21. Ito K, Hallifax D, Obach R, Houston J. (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-44.
22. Jaakkola T, Backman J, Neuvonen M, et al. (2006). Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 61: 70-8.
23. Jann M, ZumBrunnen T, Tenjarla S, et al. (1998). Relative bioavailabil-ity of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 18:288-94.
24. Jolliet P, Nion S, Allain-Veyrac G, et al. (2007). Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res 56:11-17.
25. Kajosaari L, Jaakkola T, Neuvonen P, Backman J. (2006). Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217-23.
26. Korzekwa KR, Nagar S, Tucker J, et al. (2012). Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 40:865-76.
27. Krentz AJ, Bailey CJ, Melander A. (2000). Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ 321:252-3.
28. Lazarou J, Pomeranz BH, Corey PN. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-5.
29. Lim H, Duczak NJ, Brougham L, et al. (2005). Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211-19.
30. Lyrenås EB, Olsson EH, Arvidsson UC, et al. (1997). Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 20:413-18.
31. Margolis JM, Obach RS. (2003). Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-11.
32. Masaoka T, Tack J. (2009). Gastroparesis: current concepts and management. Gut Liver 3:166-73.
33. Meuldermans W, Hurkmans R, Swysen E, et al. (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 6:49-60.
34. Michaud V, Turgeon J. (2010). Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 4:69-76.
35. Naoumova RP, Kindler H, Leccisotti L, et al. (2007). Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 50:2051-8.
36. Obach RS. (1996). The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047-9.
37. Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-69.
38. Obach R, Walsky R, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-55.
39. Orr ST, Ripp SL, Ballard TE, et al. (2012). Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55:4896-933.
40. Polasek T, Elliot D, Lewis B, Miners J. (2004). Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996-1007.
41. Reddymasu S, Soykan I, McCallum R. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102:2036-45.
42. Sahi J, Black C, Hamilton G, et al. (2003). Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439-46.
43. Schinkel AH. (1999). P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-94.
44. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-24.
45. Segel I. (1993). Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. Wiley.
46. Simard C, Michaud V, Gibbs B, et al. (2004). Identification of the cytochrome P450 enzymes involved in the metabolism of domper-idone. Xenobiotica 34:1013-23.
47. Tran TH, Von Moltke LL, Venkatakrishnan K, et al. (2002). Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-5.
48. Ung D, Parkman H, Nagar S. (2009). Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica 39:749-56.
49. Villikka K, Kivistö K, Neuvonen P. (1999). The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 65:377-81.
50. Ward B, Morocho A, Kandil A, et al. (2004). Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-87.
51. Weiss J, Sauer A, Herzog M, et al. (2009). Interaction of thiazolidine-diones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 84:264-70.
52. Wittayalertpanya S, Chompootaweep S, Thaworn N. (2006). The pharmacokinetics of pioglitazone in Thai healthy subjects. J Med Assoc Thai 89:2116-22.
53. Wong H, Ozalp Y, Lainesse A, Alpan R. (2004). In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. Arzneimittelforschung 54:618-24.
54. Wu M, Gao L, Cai X, Wang G. (2002). Determination of domperidone in human plasma by LC-MS and its pharma-cokinetics in healthy Chinese volunteers. Acta Pharmacol Sin 23: 285-8.
55. Youssef AS, Argikar UA, Pathikonda M, et al. (2013). Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. Xenobiotica 43:1073-83.
56. Zhang L, Zhang YD, Zhao P, Huang SM. (2009). Predicting drug-drug interactions: an FDA perspective. The AAPS J 11: 300-6.
57. Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.